"Mucopolysaccharidosis Syndrome in a 9-Year-old Boy: Oral-dental Management and Diagnostic Considerations": a Case Report

Overview

Journal BMC Oral Health

Publisher Biomed Central

Specialty Dentistry

Date 2024 Sep 28

PMID 39334095

Authors

Nosrat Nourbakhsh

Elahe Asnaashari Esfahani

Affiliations

Soon will be listed here.

Abstract

Background: Mucopolysaccharidosis (MPS) comprises a group of metabolic diseases with a disorder in the function of lysosomal enzymes that lead to the accumulation of glycosaminoglycans (mucopolysaccharides) (Kubaski et al. in Diagnostics 10:161, 2020; Hampe et al. in Cells 9:1838, 2020; Tomatsu et al. Mol Genet Metab 110(1-2):42-53, 2013). At least seven variants of this disorder have been identified to date (Muenzer et al. in Pediatrics 124(6):e1228-e1239, 2009; Muenzer et al. in Eur J Pediatr 171:181-8, 2012). this study aims to report a case of mucopolysaccharidosis in a 9-year-old child. Also, the treatments and dental observations made for the child have been described. Also, a review of past articles has been done to report the types of diseases, medical and dental considerations, etc. of this disease.

Case Description: the present case report describes the orofacial and systemic characteristics, diagnostic methods, and dental management of a 9-year-old boy with MPS with a one-year follow-up in association with a brief review of past articles.

Conclusion: Since MPS patients have many changes in their oral and dental structures, they pose many challenges for dentists. Also, these patients need considerations in dentistry due to the involvement of different body organs. Knowing the oral-dental and systemic problems of these patients can help their dentists to provide effective and safe treatment for them.

References

Li Y, Liu D, Yu Y . Case Report: Mucopolysaccharidosis Type I Treatment With α-L-Iduronidase Replacement Therapy. Front Pediatr. 2022; 10:823044. PMC: 9010773. DOI: 10.3389/fped.2022.823044. View

Tomatsu S, Fujii T, Fukushi M, Oguma T, Shimada T, Maeda M . Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab. 2013; 110(1-2):42-53. PMC: 4047214. DOI: 10.1016/j.ymgme.2013.06.007. View

Lange M, Teive H, Troiano A, Bitencourt M, Funke V, Setubal D . Bone marrow transplantation in patients with storage diseases: a developing country experience. Arq Neuropsiquiatr. 2006; 64(1):1-4. DOI: 10.1590/s0004-282x2006000100001. View

Muenzer J, Wraith J, Clarke L . Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009; 123(1):19-29. DOI: 10.1542/peds.2008-0416. View

Zhou J, Lin J, Leung W, Wang L . A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res. 2020; 9(1):1-9. PMC: 7062595. DOI: 10.5582/irdr.2020.01011. View

Shapiro E, Escolar M, Delaney K, Mitchell J . Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses. Mol Genet Metab. 2017; 122S:8-16. DOI: 10.1016/j.ymgme.2017.09.007. View

Bilgin H, Ayaz E . The importance of skeletal x-ray screening for dysostosis multiplex in the early diagnosis of mucopolysaccharidosis. Clin Imaging. 2023; 105:110018. DOI: 10.1016/j.clinimag.2023.110018. View

Giugliani R, Harmatz P, Wraith J . Management guidelines for mucopolysaccharidosis VI. Pediatrics. 2007; 120(2):405-18. DOI: 10.1542/peds.2006-2184. View

de Almeida-Barros R, Oka S, Pordeus A, de Medeiros P, Bento P, Godoy G . Oral and systemic manifestations of mucopolysaccharidosis type VI: a report of seven cases. Quintessence Int. 2012; 43(3):e32-8. View

10.

Sheiham A . Oral health, general health and quality of life. Bull World Health Organ. 2005; 83(9):644. PMC: 2626333. DOI: /S0042-96862005000900004. View

11.

Celik B, Tomatsu S, Tomatsu S, Khan S . Epidemiology of Mucopolysaccharidoses Update. Diagnostics (Basel). 2021; 11(2). PMC: 7916572. DOI: 10.3390/diagnostics11020273. View

12.

Tomatsu S, Montano A, Oikawa H, Smith M, Barrera L, Chinen Y . Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011; 12(6):931-45. DOI: 10.2174/138920111795542615. View

13.

Sarmento D, Carvalho S, Sousa Melo S, Alves Fonseca F, Diniz D, Bento P . Mucopolysaccharidosis: radiographic findings in a series of 16 cases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120(6):e240-6. DOI: 10.1016/j.oooo.2015.08.009. View

14.

Dickson P, Kaitila I, Harmatz P, Mlikotic A, Chen A, Victoroff A . Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I. Mol Genet Metab. 2015; 116(1-2):69-74. PMC: 4572891. DOI: 10.1016/j.ymgme.2015.07.005. View

15.

Muenzer J, Beck M, Eng C, Escolar M, Giugliani R, Guffon N . Multidisciplinary management of Hunter syndrome. Pediatrics. 2009; 124(6):e1228-39. DOI: 10.1542/peds.2008-0999. View

16.

Scarpa M, Almassy Z, Beck M, Bodamer O, Bruce I, De Meirleir L . Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011; 6:72. PMC: 3223498. DOI: 10.1186/1750-1172-6-72. View

17.

Fenzl C, Teramoto K, Moshirfar M . Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses. Clin Ophthalmol. 2015; 9:1633-44. PMC: 4567234. DOI: 10.2147/OPTH.S78368. View

18.

Noh H, Lee J . Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther. 2014; 39(3):215-24. DOI: 10.1111/jcpt.12136. View

19.

Arn P, Whitley C, Wraith J, Webb H, Underhill L, Rangachari L . High rate of postoperative mortality in patients with mucopolysaccharidosis I: findings from the MPS I Registry. J Pediatr Surg. 2012; 47(3):477-84. DOI: 10.1016/j.jpedsurg.2011.09.042. View

20.

Alves Fonseca F, Sarmento D, Vasconcelos Medeiros P, Diniz D, Dos Santos M . Patients with mucopolysaccharidosis have tendencies towards vertical facial growth. J Oral Maxillofac Surg. 2014; 72(12):2539-46. DOI: 10.1016/j.joms.2014.07.006. View